357
Participants
Start Date
June 30, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
Placebo
Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
CAT-354 150 mg
CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
CAT-354 300 mg
CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
CAT-354 600 mg
CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, Plovdiv
Research Site, Stara Zagora
Research Site, Rousse
Research Site, Burgas
Research Site, Varna
Research Site, Berlin
Research Site, Berlin
Research Site, Mainz
Research Site, Frankfurt am Main
Research Site, Lich
Research Site, Timisoara Timis
Research Site, Arad
Research Site, Arad
Research Site, Cluj-Napoca
Research Site, Rousse
Research Site, Sofia
Research Site, Sofia III
Research Site, Sofia II
Research Site, Stara Zagora
Research Site, Varna
Research Site, Berlin
Research Site, Frankfurt am Main
Research Site, Landsberg A. Lech
Research Site, Mainz
Research Site, Bielsko-Biala
Research Site, Lodz
Research Site, Pikary Slaskie
Research Site, Warsaw
Research Site, Warszawa II
Research Site, Wroclaw
Research Site, Zabrze
Research Site, Zabrze II
Research Site, Arad
Research Site, Bucharest
Research Site, Cluj-Napoca
Research Site, Deva
Research Site, Timișoara
Research Site, Cambridge
Research Site, Leicester
Research Site, Manchester
Research Site, Gdansk
Research Site, Lodz
Research Site, Skalskie
Research Site, Warsaw
Research Site, Warsazawa
Research Site, Wroclaw
Research Site, Zabrze
Research Site, Bucharest
Research Site, Bucharest
Research Site, Bucharest
Research Site, Deva
Research Site, Wythenshawe
Research Site, Cambridge
Research Site, Leicester
Lead Sponsor
MedImmune LLC
INDUSTRY